BONESUPPORT HOLDING AB (publ) – publishes Q1 2024 Interim report
Published: 2024-04-25
BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the first quarter 2024.
THE GROWTH JOURNEY CONTINUES
JANUARY – MARCH 2024
- Net sales increased by 54 percent (54 percent at constant exchange rates) and amounted to SEK 184.4 million (119.7).
- The North America (NA) segment reported a sales growth of 65 percent (65 percent at constant exchange rate).
- The Europe & Rest of the World (EUROW) segment reported a sales growth of 27 percent (24 percent at constant exchange rates).
- The gross margin amounted to 92.6 percent (90.5).
- The operating result before effects from the Group’s incentive programs amounted to SEK 41.6 million (4.6). Reported operating result amounted to SEK 32.3 million (0.8).
- Earnings per share before and after dilution were SEK 0.33 (0.00).
“Successful regulatory milestones and continued strong growth.” Emil Billbäck, CEO
EVENTS DURING THE REPORTING PERIOD
- In March, the FDA announced that CERAMENT BONE VOID FILLER has been approved for use in Spine Inter Body Fusion (IBF) in the US.
- In March, the FDA announced that CERAMENT G was approved for use in open fractures in the US.
EVENTS AFTER THE REPORTING PERIOD
- Nothing to report.
For more information contact:
BONESUPPORT Holding AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70
Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com
Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se
This information is information that BONESUPPORT Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-04-25 08:00 CEST.
About BONESUPPORT™
BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 591 million in 2023. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.
Attachments
